Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Mallinckrodt PLC    MNK   IE00BBGT3753

MALLINCKRODT PLC (MNK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Mallinckrodt : To Present At Deutsche Bank's 43rd Annual Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2018 | 11:46am CEST

STAINES-UPON-THAMES - Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, May 9, 2018, at Deutsche Bank's 43rd Annual Healthcare Conference at the Intercontinental Hotel Boston, 510 Atlantic Ave., in Boston.

Mark Trudeau, President and Chief Executive Officer, and Dr. Steven Romano, Executive Vice President and Chief Scientific Officer, will represent the company in a fireside chat at 12:50 p.m. Eastern.

ABOUT MALLINCKRODT

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Contact:

Daniel J. Speciale

Tel: 314-654-3638

Email: [email protected]

(C) 2018 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
DEUTSCHE BANK -0.39% 10.312 Delayed Quote.-34.79%
MALLINCKRODT PLC 0.69% 21.905 Delayed Quote.-3.28%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MALLINCKRODT PLC
07/11MALLINCKRODT : New Health Economic Data on Mallinckrodt's OFIRMEV Injection Publ..
AQ
07/11Free Stock Performance Review on Mallinckrodt and Three Additional Generic Dr..
AC
07/09MALLINCKRODT : New Health Economic Data on Mallinckrodt's OFIRMEV® (Acetaminophe..
PR
07/05MALLINCKRODT : Reports Interim Findings Of H.P. Acthar® Gel Repository Corticotr..
AQ
07/03MALLINCKRODT : Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel A..
AQ
06/30MALLINCKRODT : Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (..
AQ
06/30MALLINCKRODT : rheumatoid arthritis study for H.P. Acthar Gel
AQ
06/28MALLINCKRODT : Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel ..
PR
06/28MALLINCKRODT : Reports Interim Findings Of H.P. Acthar® Gel Repository Corticotr..
AQ
06/26MALLINCKRODT : Launches Scientific Advisory Council
AQ
More news
News from SeekingAlpha
11:10aBig Pharma in the red on ramped up pressure on drug prices 
07/16The Smart Way To Find Undervalued Stocks 
07/06S&P 1500 Misfit Stocks 
07/05Healthcare Dashboard - Update 
06/08MALLINCKRODT : The Cheapest Stock In Global Healthcare 
Financials ($)
Sales 2018 2 467 M
EBIT 2018 962 M
Net income 2018 137 M
Debt 2018 5 557 M
Yield 2018 -
P/E ratio 2018 13,62
P/E ratio 2019 11,70
EV / Sales 2018 2,98x
EV / Sales 2019 2,58x
Capitalization 1 795 M
Chart MALLINCKRODT PLC
Duration : Period :
Mallinckrodt PLC Technical Analysis Chart | MNK | IE00BBGT3753 | 4-Traders
Technical analysis trends MALLINCKRODT PLC
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 20,5 $
Spread / Average Target -6,0%
EPS Revisions
Managers
NameTitle
Mark C. Trudeau President, Chief Executive Officer & Director
Angus C. Russell Chairman
Frank Scholz EVP-Global Operations & Digital Innovation Officer
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Steven Romano Chief Scientific Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
MALLINCKRODT PLC-3.28%1 795
ABBVIE-2.39%151 404
MERCK KGAA-4.74%12 859
KYOWA HAKKO KIRIN CO LTD-1.49%11 440
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD98.64%11 422
JAZZ PHARMACEUTICALS PLC30.75%10 586